Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

626 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
SARS-CoV-2 vaccines: 'Warp Speed' needs mind melds not warped minds.
Moore JP, Klasse PJ. Moore JP, et al. J Virol. 2020 Jun 26:JVI.01083-20. doi: 10.1128/JVI.01083-20. Online ahead of print. J Virol. 2020. PMID: 32591466 Free article. Review.
A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells.
Moore JP, Sattentau QJ, Klasse PJ, Burkly LC. Moore JP, et al. J Virol. 1992 Aug;66(8):4784-93. doi: 10.1128/JVI.66.8.4784-4793.1992. J Virol. 1992. PMID: 1378510 Free PMC article.
Kinetics of the HIV-CD4 interactions and virus-cell fusion.
Klasse PJ, Moore JP. Klasse PJ, et al. AIDS. 1992 Mar;6(3):325-7. doi: 10.1097/00002030-199203000-00011. AIDS. 1992. PMID: 1567578 No abstract available.
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.
Gorny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, Burda S, Boots LJ, Zolla-Pazner S. Gorny MK, et al. J Virol. 1994 Dec;68(12):8312-20. doi: 10.1128/JVI.68.12.8312-8320.1994. J Virol. 1994. PMID: 7525987 Free PMC article.
Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.
Klasse PJ, Moore JP. Klasse PJ, et al. J Virol. 1996 Jun;70(6):3668-77. doi: 10.1128/JVI.70.6.3668-3677.1996. J Virol. 1996. PMID: 8648701 Free PMC article.
Moore and D. D. Ho, AIDS 9 [suppl. A]:5117-5136, 1995). We developed a quantitative model to explain the neutralization resistance of PI. ...
Moore and D. D. Ho, AIDS 9 [suppl. A]:5117-5136, 1995). We developed a quantitative model to explain the neutralization resistance of
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.
Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP. Sanders RW, et al. J Virol. 2002 Jul;76(14):7293-305. doi: 10.1128/jvi.76.14.7293-7305.2002. J Virol. 2002. PMID: 12072528 Free PMC article.
Moore, and H. Katinger, J. Virol. 70:1100-1108, 1996). In a biochemical study, we digested recombinant gp120 with various glycosidase enzymes of known specificities and showed that the 2G12 epitope is lost when gp120 is treated with mannosidases. ...
Moore, and H. Katinger, J. Virol. 70:1100-1108, 1996). In a biochemical study, we digested recombinant gp120 with various glycosidase
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R, Paluch M, Berkhout B, Maddon PJ, Olson WC, Lu M, Moore JP. Sanders RW, et al. J Virol. 2002 Sep;76(17):8875-89. doi: 10.1128/jvi.76.17.8875-8889.2002. J Virol. 2002. PMID: 12163607 Free PMC article.
Moore, and W. C. Olson, J. Virol. 76:7760-7776, 2002). Here we describe modifications of SOS gp140 that increase its trimer stability. ...
Moore, and W. C. Olson, J. Virol. 76:7760-7776, 2002). Here we describe modifications of SOS gp140 that increase its trimer stability
626 results
Jump to page
Feedback